Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

787
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
787
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

621
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
621
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

643
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
643

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular-Based Risk Prediction Models for Recurrence After Curative Treatment of Early-Stage Lung Cancer: A Systematic Review and Meta-Analysis.

Thoracic cancer·2026
Same author

Long-term survival in patients discharged alive from hospital following an intensive care unit admission with sepsis or septic shock in Australia and New Zealand: an observational cohort study.

The Lancet regional health. Western Pacific·2026
Same author

Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population-Based Study.

Diabetes, obesity & metabolism·2026
Same author

Predicting device-related complications among women undergoing breast implant surgeries.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2026
Same author

Semiparametric accelerated failure time models with time-varying covariates under partly interval censoring.

BMC medical research methodology·2026
Same author

Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes: Outcomes of a Population-Based Real-World Study.

Diabetes technology & therapeutics·2026

Related Experiment Video

Updated: Feb 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis.

Getayeneh Antehunegn Tesema1,2, Rob G Stirling3,4, Win Wah5

  • 1School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Immunity, Inflammation and Disease
|February 18, 2026
PubMed
Summary

Early mortality after Systemic Anticancer Therapy (SACT) for lung cancer varies geographically. Identifying high-risk patients and areas is crucial for personalized treatment strategies.

Keywords:
Bayesian multilevel modelingVictoriaearly mortalitylung cancerspatiotemporal analysissystemic anticancer therapy

More Related Videos

Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells
08:54

Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells

Published on: May 20, 2020

10.1K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Related Experiment Videos

Last Updated: Feb 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells
08:54

Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells

Published on: May 20, 2020

10.1K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Area of Science:

  • Oncology
  • Public Health
  • Biostatistics

Background:

  • Early mortality following Systemic Anticancer Therapy (SACT) for lung cancer is a significant concern despite treatment advances.
  • Identifying high-risk patients is essential for optimizing treatment decisions, especially when SACT benefits may be limited.

Purpose of the Study:

  • To quantify spatiotemporal patterns of early mortality after SACT in lung cancer patients.
  • To examine individual and area-level risk factors contributing to early mortality.

Main Methods:

  • Secondary analysis of data from the Victorian Lung Cancer Registry.
  • Application of Bayesian spatiotemporal multilevel models to assess risk factors.
  • Reporting of Adjusted Odds Ratios (AORs) with 95% Credible Intervals (Crl) for statistical significance.

Main Results:

  • Significant spatiotemporal variation in early mortality post-SACT was observed.
  • Increased mortality risk was associated with older age (≥60 years), advanced clinical stages (II-IV), comorbidities, and poor performance status.
  • Multidisciplinary meeting presentation and supportive care screening were linked to reduced mortality risk.

Conclusions:

  • Substantial geographic and temporal variations in early mortality following SACT underscore the need for targeted, risk-stratified treatment approaches.
  • Patients with advanced disease, comorbidities, poor performance status, and those in high-risk areas require specific attention for optimized SACT strategies.